5040 T3D4981 Pioglitazone Pioglitazone is used for the treatment of diabetes mellitus type 2. Pioglitazone selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPAR-gamma). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the lipidic, muscular tissues and in the liver. 111025-46-8 4829 C19H20N2O3S 183-184 °C mg/mL Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption. Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic β cells. Hepatic Hypogycemia; LD<sub>50</sub>=mg/kg (orally in rat) 2A, probably carcinogenic to humans. (L135) Treatment of Type II diabetes mellitus 2014-10-14T21:18:37Z 2026-03-26T18:38:13Z Pioglitazone C07675 8228 C060836 DB01132 true CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1 C19H20N2O3S InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23) HYAFETHFCAUJAY-UHFFFAOYSA-N 356.439 356.119463206 Exogenous Solid 2.3 HMDB15264 CHEMBL595 4663 <p>Chandra Khanduri, Yatendra Kumar, Atulya Panda, Suchitra Chakraborty, Mukesh Sharma, &#8220;Process for the preparation of pioglitazone.&#8221; U.S. Patent US20070078170, issued April 05, 2007.</p> CHEM003935 DTXSID3037129 NS00000599 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione